Pre-clinical assessment of anti-vascular drugs using quantitative dynamic contrast-enhanced MRI

International Journal of Medical Engineering and Informatics

Volumn 4, Issue 4, 2012, Pages 362-372

  Linnik, Inna V ^a   Williams, Steve R ^a   Davies, Karen E ^a   McGown, Alan T ^b   Hadfield, John A ^b   Buckley, David L ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF SALFORD   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Anti cancer agent; Dynamic contrast enhanced MRI; Radiation induced fibrosarcoma; Tumour model

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN; COMBRETASTATIN A4; COMBRETASTATIN QUINONE 6; FLUOROCOMBRETASTATIN 3; GADOLINIUM PENTETATE; METHYLCOMBRETASTATIN 4; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VEGETABLE OIL;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; EXTRACELLULAR SPACE; EXTRAVASCULAR SPACE; FEMALE; FIBROSARCOMA; HAZELNUT; IN VIVO STUDY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RADIATION INDUCED NEOPLASM; RADIATION MEASUREMENT; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR VASCULARIZATION;

EID: 84869782144     PISSN: 17550653     EISSN: 17550661     Source Type: Journal    
DOI: 10.1504/IJMEI.2012.050277     Document Type: Article

References (29)

1. Beauregard, D.A., Hill, S.A., Chaplin, D.J. and Brindle, K.M. (2001) 'The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability', Cancer Res., Vol. 61, No. 18, pp.6811-6815.
2. Benjaminsen, I.C., Graff, B.A., Brurberg, K.G. and Rofstad, E.K. (2004) 'Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts', Magn. Reson. Med., Vol. 52, No. 2, pp.269-276.
3. Checkley, D., Tessier, J.J., Wedge, S.R., Dukes, M., Kendrew, J., Curry, B., Middleton, B. and Waterton, J.C. (2003) 'Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts', Magn. Reson. Imaging, Vol. 21, No. 5, pp.475-482.
4. Cooney, M.M., Radivoyevitch, T., Dowlati, A, Overmoyer, B., Levitan, N., Robertson, K., Levine, S.L., DeCaro, K., Buchter, C., Taylor, A., Stamble, B.S. and Remick, S.C. (2004) 'Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer', Clin. Cancer Res., Vol. 10, No. 1, pp.96-100.
5. Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R. and Chaplin, D.J. (1997) 'Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature', Cancer Res., Vol. 57, No. 10, pp.1829-1834.
6. Davis, P.D., Tozer, G.M., Naylor, M.A., Thomson, P., Lewis, G. and Hill, S.A. (2002) 'Enhancement of vascular targeting by inhibitors of nitric oxide synthase', Int. J. Radiat. Oncol. Biol. Phys., Vol. 54, No. 5, pp.1532-1536.
7. Dowlati, A., Robertson, K., Cooney, M., Petros, W., Stratford, M., Jesberger, J., Rafie, N., Overmoyer, B., Makkar, V., Stambler, B., Taylor, A., Waas, J., Lewin, J., McCrae, K. and Remick, S. (2002) 'A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer', Cancer Res., Vol. 62, No. 12, pp.3408-3416.
8. Folkman, J. (1990) 'What is the evidence that tumors are angiogenesis dependent?', J. Natl. Cancer Inst., Vol. 82, No. 1, pp.4-6.
9. Galbraith, S.M., Maxwell, R.J., Lodge, M.A., Tozer, G.M., Wilson, J., Taylor, N.J., Stirling, J.J., Sena, L., Padhani, A.R. and Rustin, G.J. (2003) 'Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging', J. Clin. Oncol., Vol. 21, No. 15, pp.2831-2842.
10. Gaukroger. K., Hadfield, J.A., Lawrence, N., Nolan, S. and McGown, A. (2003) 'Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?', Org. Biomol. Chem., Vol. 1, No. 17, pp.3033-3037.
11. Hadfield, J., McGown, A.T, Mayalarp, S., Land, E.J., Hamblett, I, Gaukroger, K., Lawrence, N.J., Hepworth, L.A. and Butler, J. (2007) Substituted stilbenes and their reactions, US Patent 7,220,784.
12. Hadfield, J.A., Gaukroger, K., Hirst, N., Weston, A.P., Lawrence, N.J. and McGown, A.T. (2005) 'Synthesis and evaluation of double bond substituted combretastatins', Eur. J. Med. Chem., Vol. 40, No. 6, pp.529-541.
13. Iyer, S., Chaplin, D.J., Rosenthal, D.S., Boulares, A.H., Li, L.Y. and Smulson, M.E. (1998) 'Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4', Cancer Res., Vol. 58, No. 20, pp.4510-4514.
14. Johannes, F., Blizard, D.A., Lionikas, A., Lang, D.H., Vandenbergh, D.J., Stout, J.T., Strauss, J.A., McClearn, G.E. and Vogler, G.P. (2006) 'QTL influencing baseline hematocrit in the C57BL/6J and DBA/2J lineage: age-related effects', Mamm. Genome, Vol. 17, No. 6, pp.689-699.
15. Lawrence, N.L., Hepworth, L.A., Rennison, D., McGown, A.T. and Hadfield, J.A. (2003) 'Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4', J. Fluor. Chem., Vol. 123, No. 1, pp.101-108.
16. Leach, M.O., Brindle, K.M., Evelhoch, J.L., Griffiths, J.R., Horsman, M.R., Jackson, A., Jayson, G.C., Judson, I.R., Knopp, M.V., Maxwell, R.J., McIntyre, D., Padhani, A.R., Price, P., Rathbone, R., Rustin, G.J., Tofts, P.S., Tozer, G.M., Vennart, W., Waterton, J.C., Williams, S.R. and Workman, P. (2005) 'The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations', Br. J. Cancer, Vol. 92, No. 9, pp.1599-1610.
17. Linnik, I.V., Buckley, D.L. and Williams, S.R. (2005) 'Effects of an anti-Angiogenic and anti-Tumour antibody on tumour vasculature determined by dynamic contrast enhanced MRI', presented at the 13th Scientific Meeting International Society for Magnetic Resonance in Medicine, 7-13 May 2005, Florida, USA.
18. Linnik, I.V., Williams, S.R., Davies, K.E., Murphy, P.S., Giorgio-Miller, A.D. and Buckley, D.L. (2006) 'Development of a murine isogenic graft model of endometriosis: monitoring by dynamic contrast-enhanced MRI', presented at the 14th Scientific Meeting International Society for Magnetic Resonance in Medicine, 6-12 May, 2000, Seattle, USA.
19. Lyng, H., Dahle, G.A., Kaalhus, O., Skretting, A. and Rofstad, E.K. (1998) 'Measurement of perfusion rate in human melanoma xenografts by contrast-enhanced magnetic resonance imaging', Magn. Reson. Med., Vol. 40, No. 1, pp.89-98.
20. Maxwell, R.J., Wilson, J., Prise, V.E., Vojnovic, B., Rustin, G.J., Lodge, M.A. and Tozer, G.M. (2002) 'Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI', NMR Biomed., Vol. 15, No. 2, pp.89-98.
21. Patlak, C.S., Blasberg, R.G. and Fenstermacher, J.D. (1983) 'Graphical evaluation of blood-To-brain transfer constants from multiple-Time uptake data', J. Cereb. Blood Flow Metab., Vol. 3, No. 1, pp.1-7.
22. Pettit, G.R., Temple, C., Jr., Narayanan, V.L., Varma, R., Simpson, M.J. and Boyd, M.R., Rener, G.A. and Bansal, N. (1995) 'Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs', Anticancer Drug Des., Vol. 10, No. 4, pp.299-309.
23. Pradel, C., Siauve, N., Bruneteau, G., Clement, O., de Bazelaire, C., Frouin, F., Wedge. S.R., Tessier, J.L., Robert, P.H., Frija, G. and Cuenod, C.A. (2003) 'Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media', Magn. Reson. Imag., Vol. 21, No. 8, pp.845-851.
24. Tofts, P.S. and Kermode, A.G. (1991) 'Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts', Magn. Reson. Med., Vol. 17, No. 7, pp.357-367.
25. Tozer, G.M., Prise, V.E., Wilson, J., Locke, R.J., Vojnovic. B., Stratford. M.R., Dennis, M.F. and Chaplin, D.J. (1999) 'Combretastatin A-4 phosphate as a tumor vascular-Targeting agent: early effects in tumors and normal tissues', Cancer Res., Vol. 59, No. 3, pp.1626-1634.
26. Twentyman, P., Brown, J.M., Gray, J., Franko, A., Scoles, M. and Kallman, R. (1980) 'A new mouse tumor model system (RIF-1) for comparison of end-point studies', J. Natl. Cancer Inst., Vol. 64, No. 3, pp.595-604.
27. West, C.M. and Price, P. (2004) 'Combretastatin A4 phosphate', Anticancer Drugs, Vol. 15, pp.179-187.
28. Woods, J.A., Hadfield, J.A., Pettit, G.R., Fox, B.W. and McGown, A.T. (1995) 'The interaction with tubulin of a series of stilbenes based on combretastatin A-4', Br. J. Cancer., Vol. 71, No. 3, pp.705-711.
29. Zhou, R., Pickup, S., Yankeelov, T.E., Springer, C.S., Jr. and Glickson, J.D. (2004) 'Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange', Magn. Reson. Med., Vol. 52, No. 4, pp.248-257.